Results 281 to 290 of about 16,792,438 (305)

Line by Line

2018
openaire   +1 more source

Next-generation characterization of the Cancer Cell Line Encyclopedia

Nature, 2019
Mahmoud Mahdi Ghandi, Franklin W Huang, Gregory V Kryukov   +2 more
exaly  

Lines, Lines, Lines

openaire   +1 more source

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer
exaly  

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Lancet, The, 2014
Edward B Garon, Oscar Arrieta, Keunchil Park   +2 more
exaly  

Anal cancer: Current standards in care and recent changes in practice

Ca-A Cancer Journal for Clinicians, 2015
exaly  

Isolated Lines

2008
Jean-Michel Hartmann, Christian Boulet, Daniel Robert   +2 more
openaire   +1 more source

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Lancet, The, 2012
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold   +2 more
exaly  

Wallace's Line

British Journal of Dermatology, 1986
C M, Rowland Payne, A C, Branfoot
openaire   +2 more sources

Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma

Ca-A Cancer Journal for Clinicians, 2018
exaly